230 related articles for article (PubMed ID: 24290219)
1. Allogeneic stem cell transplantation and targeted immunotherapy for multiple myeloma.
Danylesko I; Shimoni A; Nagler A
Clin Lymphoma Myeloma Leuk; 2013 Sep; 13 Suppl 2():S330-48. PubMed ID: 24290219
[TBL] [Abstract][Full Text] [Related]
2. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.
Kuruvilla J; Shepherd JD; Sutherland HJ; Nevill TJ; Nitta J; Le A; Forrest DL; Hogge DE; Lavoie JC; Nantel SH; Toze CL; Smith CA; Barnett MJ; Song KW
Biol Blood Marrow Transplant; 2007 Aug; 13(8):925-31. PubMed ID: 17640596
[TBL] [Abstract][Full Text] [Related]
3. Mini-Midi-Maxi? How to harness the graft-versus-myeloma effect and target molecular remission after allogeneic stem cell transplantation.
Kröger N
Leukemia; 2007 Sep; 21(9):1851-8. PubMed ID: 17568819
[TBL] [Abstract][Full Text] [Related]
4. Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up.
Björkstrand B; Iacobelli S; Hegenbart U; Gruber A; Greinix H; Volin L; Narni F; Musto P; Beksac M; Bosi A; Milone G; Corradini P; Goldschmidt H; de Witte T; Morris C; Niederwieser D; Gahrton G
J Clin Oncol; 2011 Aug; 29(22):3016-22. PubMed ID: 21730266
[TBL] [Abstract][Full Text] [Related]
5. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
6. Partial T cell-depleted allogeneic stem cell transplantation following reduced-intensity conditioning creates a platform for immunotherapy with donor lymphocyte infusion and recipient dendritic cell vaccination in multiple myeloma.
Levenga H; Schaap N; Maas F; Esendam B; Fredrix H; Greupink-Draaisma A; de Witte T; Dolstra H; Raymakers R
Biol Blood Marrow Transplant; 2010 Mar; 16(3):320-32. PubMed ID: 19835972
[TBL] [Abstract][Full Text] [Related]
7. In pursuit of the allo-immune response in multiple myeloma: where do we go from here?
Cook G; Bird JM; Marks DI
Bone Marrow Transplant; 2009 Jan; 43(2):91-9. PubMed ID: 19079310
[TBL] [Abstract][Full Text] [Related]
8. Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity.
Peggs KS; Mackinnon S; Williams CD; D'Sa S; Thuraisundaram D; Kyriakou C; Morris EC; Hale G; Waldmann H; Linch DC; Goldstone AH; Yong K
Biol Blood Marrow Transplant; 2003 Apr; 9(4):257-65. PubMed ID: 12720218
[TBL] [Abstract][Full Text] [Related]
9. The current status of hematopoietic stem cell transplantation for multiple myeloma.
Bensinger WI
Clin Adv Hematol Oncol; 2004 Jan; 2(1):46-52. PubMed ID: 16163159
[TBL] [Abstract][Full Text] [Related]
10. Long-term follow-up of an intensified myeloablative conditioning regimen with in vivo T cell depletion followed by allografting in patients with advanced multiple myeloma.
Kröger N; Einsele H; Derigs G; Wandt H; Krüll A; Zander A
Biol Blood Marrow Transplant; 2010 Jun; 16(6):861-4. PubMed ID: 20139025
[TBL] [Abstract][Full Text] [Related]
11. Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous-allogeneic tandem transplantation in patients with multiple myeloma.
Kröger N; Badbaran A; Zabelina T; Ayuk F; Wolschke C; Alchalby H; Klyuchnikov E; Atanackovic D; Schilling G; Hansen T; Schwarz S; Heinzelmann M; Zeschke S; Bacher U; Stübig T; Fehse B; Zander AR
Biol Blood Marrow Transplant; 2013 Mar; 19(3):398-404. PubMed ID: 23078786
[TBL] [Abstract][Full Text] [Related]
12. Allogeneic stem cell transplantation for multiple myeloma.
Bensinger W
Hematol Oncol Clin North Am; 2014 Oct; 28(5):891-902. PubMed ID: 25212888
[TBL] [Abstract][Full Text] [Related]
13. Progress in allogeneic transplantation for multiple myeloma.
Gahrton G
Eur J Haematol; 2010 Oct; 85(4):279-89. PubMed ID: 20608964
[TBL] [Abstract][Full Text] [Related]
14. Results of autologous and allogeneic hematopoietic cell transplant therapy for multiple myeloma.
Arora M; McGlave PB; Burns LJ; Miller JS; Barke JN; Defor TE; Weisdorf DJ
Bone Marrow Transplant; 2005 Jun; 35(12):1133-40. PubMed ID: 15834435
[TBL] [Abstract][Full Text] [Related]
15. Clinical and molecular remission following reduced intensity conditioning and allogeneic transplantation in a patient with refractory multiple myeloma.
Dodero A; Perfetti V; Ciceri F; Corradini P
Haematologica; 2002 Dec; 87(12):ECR41. PubMed ID: 12495912
[No Abstract] [Full Text] [Related]
16. Reduced-intensity allogeneic hematopoietic stem cell transplantation for multiple myeloma: a concise review.
Salit RB; Bishop MR
Clin Lymphoma Myeloma Leuk; 2011 Jun; 11(3):247-52. PubMed ID: 21658650
[TBL] [Abstract][Full Text] [Related]
17. [Hematopoietic stem cell transplantation in multiple myeloma].
Vela-Ojeda J; Ruiz-Esparza MA
Rev Invest Clin; 2005; 57(2):305-13. PubMed ID: 16524072
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcome after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with multiple myeloma.
El-Cheikh J; Crocchiolo R; Furst S; Stoppa AM; Ladaique P; Faucher C; Calmels B; Lemarie C; De Colella JM; Granata A; Coso D; Bouabdallah R; Chabannon C; Blaise D
Am J Hematol; 2013 May; 88(5):370-4. PubMed ID: 23460414
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic transplantation in multiple myeloma.
Gahrton G
Recent Results Cancer Res; 2011; 183():273-84. PubMed ID: 21509689
[TBL] [Abstract][Full Text] [Related]
20. Treatment of multiple myeloma.
San Miguel JF; Bladé Creixenti J; García-Sanz R
Haematologica; 1999 Jan; 84(1):36-58. PubMed ID: 10091392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]